N4 Pharma Plc
N4P.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 9.3% | -13.6% | 100% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 0% | 100% | 100% | 100% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -12,743% | -19,841.3% | -12,546% | -39,938.6% |
| Other Income/Exp. Net | £0 | -£0 | -£0 | £0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | £0 | -£0 | £0 | -£0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -13,510.8% | -17,891% | -11,645.3% | -31,899.6% |
| EPS | -0.001 | -0.002 | -0.002 | -0.003 |
| % Growth | 50% | -12.5% | 36% | – |
| EPS Diluted | -0.001 | -0.002 | -0.002 | -0.003 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | -£0 | -£0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -12,743% | -21,652.8% | -12,588.5% | -39,938.6% |